BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

424 related articles for article (PubMed ID: 15342412)

  • 1. Growth inhibition of human prostate cancer cells in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice by a ligand-specific antibody to human insulin-like growth factors.
    Goya M; Miyamoto S; Nagai K; Ohki Y; Nakamura K; Shitara K; Maeda H; Sangai T; Kodama K; Endoh Y; Ishii G; Hasebe T; Yonou H; Hatano T; Ogawa Y; Ochiai A
    Cancer Res; 2004 Sep; 64(17):6252-8. PubMed ID: 15342412
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Osteoprotegerin/osteoclastogenesis inhibitory factor decreases human prostate cancer burden in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice.
    Yonou H; Kanomata N; Goya M; Kamijo T; Yokose T; Hasebe T; Nagai K; Hatano T; Ogawa Y; Ochiai A
    Cancer Res; 2003 May; 63(9):2096-102. PubMed ID: 12727825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts.
    Fizazi K; Yang J; Peleg S; Sikes CR; Kreimann EL; Daliani D; Olive M; Raymond KA; Janus TJ; Logothetis CJ; Karsenty G; Navone NM
    Clin Cancer Res; 2003 Jul; 9(7):2587-97. PubMed ID: 12855635
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Severe combined immunodeficient-hu model of human prostate cancer metastasis to human bone.
    Nemeth JA; Harb JF; Barroso U; He Z; Grignon DJ; Cher ML
    Cancer Res; 1999 Apr; 59(8):1987-93. PubMed ID: 10213511
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blockade of paracrine supply of insulin-like growth factors using neutralizing antibodies suppresses the liver metastasis of human colorectal cancers.
    Miyamoto S; Nakamura M; Shitara K; Nakamura K; Ohki Y; Ishii G; Goya M; Kodama K; Sangai T; Maeda H; Shi-Chuang Z; Chiba T; Ochiai A
    Clin Cancer Res; 2005 May; 11(9):3494-502. PubMed ID: 15867252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I.
    Sachdev D; Li SL; Hartell JS; Fujita-Yamaguchi Y; Miller JS; Yee D
    Cancer Res; 2003 Feb; 63(3):627-35. PubMed ID: 12566306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The insulin-like growth factor axis and prostate cancer: lessons from the transgenic adenocarcinoma of mouse prostate (TRAMP) model.
    Kaplan PJ; Mohan S; Cohen P; Foster BA; Greenberg NM
    Cancer Res; 1999 May; 59(9):2203-9. PubMed ID: 10232609
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced androgen receptor signaling correlates with the androgen-refractory growth in a newly established MDA PCa 2b-hr human prostate cancer cell subline.
    Hara T; Nakamura K; Araki H; Kusaka M; Yamaoka M
    Cancer Res; 2003 Sep; 63(17):5622-8. PubMed ID: 14500404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo.
    Burtrum D; Zhu Z; Lu D; Anderson DM; Prewett M; Pereira DS; Bassi R; Abdullah R; Hooper AT; Koo H; Jimenez X; Johnson D; Apblett R; Kussie P; Bohlen P; Witte L; Hicklin DJ; Ludwig DL
    Cancer Res; 2003 Dec; 63(24):8912-21. PubMed ID: 14695208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The alpha-receptor for platelet-derived growth factor as a target for antibody-mediated inhibition of skeletal metastases from prostate cancer cells.
    Russell MR; Jamieson WL; Dolloff NG; Fatatis A
    Oncogene; 2009 Jan; 28(3):412-21. PubMed ID: 18850002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of proliferation of PC-3 human prostate cancer by antagonists of growth hormone-releasing hormone: lack of correlation with the levels of serum IGF-I and expression of tumoral IGF-II and vascular endothelial growth factor.
    Plonowski A; Schally AV; Letsch M; Krupa M; Hebert F; Busto R; Groot K; Varga JL
    Prostate; 2002 Aug; 52(3):173-82. PubMed ID: 12111694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate-specific antigen enhances bioavailability of insulin-like growth factor by degrading insulin-like growth factor binding protein 5.
    Maeda H; Yonou H; Yano K; Ishii G; Saito S; Ochiai A
    Biochem Biophys Res Commun; 2009 Apr; 381(3):311-6. PubMed ID: 19250630
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo progression of LAPC-9 and LNCaP prostate cancer models to androgen independence is associated with increased expression of insulin-like growth factor I (IGF-I) and IGF-I receptor (IGF-IR).
    Nickerson T; Chang F; Lorimer D; Smeekens SP; Sawyers CL; Pollak M
    Cancer Res; 2001 Aug; 61(16):6276-80. PubMed ID: 11507082
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Up-regulation of insulin-like growth factor axis components in human primary prostate cancer correlates with tumor grade.
    Liao Y; Abel U; Grobholz R; Hermani A; Trojan L; Angel P; Mayer D
    Hum Pathol; 2005 Nov; 36(11):1186-96. PubMed ID: 16260272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation.
    Maloney EK; McLaughlin JL; Dagdigian NE; Garrett LM; Connors KM; Zhou XM; Blättler WA; Chittenden T; Singh R
    Cancer Res; 2003 Aug; 63(16):5073-83. PubMed ID: 12941837
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Growth-inhibitory effects of human anti-insulin-like growth factor-I receptor antibody (A12) in an orthotopic nude mouse model of anaplastic thyroid carcinoma.
    Wang Z; Chakravarty G; Kim S; Yazici YD; Younes MN; Jasser SA; Santillan AA; Bucana CD; El-Naggar AK; Myers JN
    Clin Cancer Res; 2006 Aug; 12(15):4755-65. PubMed ID: 16899627
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of bone-derived insulin-like growth factors by a ligand-specific antibody suppresses the growth of human multiple myeloma in the human adult bone explanted in NOD/SCID mouse.
    Araki K; Sangai T; Miyamoto S; Maeda H; Zhang SC; Nakamura M; Ishii G; Hasebe T; Kusaka H; Akiyama T; Tokuda Y; Nagai K; Minami H; Ochiai A
    Int J Cancer; 2006 May; 118(10):2602-8. PubMed ID: 16353147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Castration-induced up-regulation of insulin-like growth factor binding protein-5 potentiates insulin-like growth factor-I activity and accelerates progression to androgen independence in prostate cancer models.
    Miyake H; Pollak M; Gleave ME
    Cancer Res; 2000 Jun; 60(11):3058-64. PubMed ID: 10850457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of human breast cancer cells with antisense RNA to the type I insulin-like growth factor receptor inhibits cell growth, suppresses tumorigenesis, alters the metastatic potential, and prolongs survival in vivo.
    Chernicky CL; Yi L; Tan H; Gan SU; Ilan J
    Cancer Gene Ther; 2000 Mar; 7(3):384-95. PubMed ID: 10766344
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Establishment of a novel species- and tissue-specific metastasis model of human prostate cancer in humanized non-obese diabetic/severe combined immunodeficient mice engrafted with human adult lung and bone.
    Yonou H; Yokose T; Kamijo T; Kanomata N; Hasebe T; Nagai K; Hatano T; Ogawa Y; Ochiai A
    Cancer Res; 2001 Mar; 61(5):2177-82. PubMed ID: 11280783
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.